1. Home
  2. WEYS vs DSGN Comparison

WEYS vs DSGN Comparison

Compare WEYS & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Weyco Group Inc.

WEYS

Weyco Group Inc.

N/A

Current Price

$31.43

Market Cap

280.9M

ML Signal

N/A

Logo Design Therapeutics Inc.

DSGN

Design Therapeutics Inc.

HOLD

Current Price

$9.35

Market Cap

504.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WEYS
DSGN
Founded
1906
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Apparel
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
280.9M
504.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
WEYS
DSGN
Price
$31.43
$9.35
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$13.50
AVG Volume (30 Days)
16.0K
503.6K
Earning Date
11-04-2025
11-05-2025
Dividend Yield
3.51%
N/A
EPS Growth
N/A
N/A
EPS
2.54
N/A
Revenue
$279,843,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$12.12
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.51
$2.60
52 Week High
$38.19
$10.31

Technical Indicators

Market Signals
Indicator
WEYS
DSGN
Relative Strength Index (RSI) 43.06 52.50
Support Level $30.57 $9.44
Resistance Level $31.98 $10.01
Average True Range (ATR) 0.96 0.57
MACD -0.34 -0.08
Stochastic Oscillator 0.00 55.47

Price Performance

Historical Comparison
WEYS
DSGN

About WEYS Weyco Group Inc.

Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale operations and the North American retail operations. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, Asia, South Africa, and Australia.

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Share on Social Networks: